APOE4驱动了肝脏蛋白质组的广泛变化,并改变了代谢功能
Colton R Lysaker1,2, Chelsea N Johnson2,3, Vivien Csikos1,2
1Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
iScience
|March 9, 2026
概括
APOE4基因变体显著改变肝功能,导致线粒体问题和代谢变化,如改变葡萄糖和脂质处理. 这会影响整体肝脏健康.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 代谢疾病 代谢疾病
背景情况:
- 脂蛋白E (APOE) 对于脂质代谢至关重要,并且与阿尔茨海默病 (AD) 风险有关.
- APOE4等位基因增加了AD风险,并与代谢缺陷有关,但其肝脏特异性影响尚不清楚.
研究的目的:
- 研究APOE基因型 (APOE3与APOE4) 对肝脏健康和新陈代谢的影响.
- 探索APOE基因型对肝功能性别特异性的影响.
主要方法:
- 使用年轻的APOE3和APOE4向的替代小鼠.
- 采用同位素诱导的多能干细胞 (iPSC) 衍生的肝细胞样细胞 (iHLC).
- 进行蛋白质和功能测试以分析代谢和线粒体变化.
主要成果:
- 在小鼠中,APOE4以性别特定的方式显著改变了肝脏线粒体功能.
- 在小鼠中,APOE4诱导了葡萄糖和脂质代谢的变化.
- 在iHLC中,APOE4损害了线粒体功能,促进了糖解,脂肪酸的使用和脂质的积累.
结论:
- APOE遗传变异直接影响肝脏线粒体功能.
- APOE基因型重新连接肝脏新陈代谢,导致代谢功能障碍.
- 这些发现突出了APOE在肝脏健康中的作用,超出了它与AD的已知关联.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
246
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
305
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
274
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
274
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
Drug Metabolism: Phase I Reactions
5.4K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
5.4K
Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57


